<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part3">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>3</PartID>
        <PartNumber>Part II</PartNumber>
        <PartSequenceNumber>3</PartSequenceNumber>
        <PartTitle>Chemotherapy</PartTitle>
        <PartChapterCount>6</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap14" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>14</ChapterID>
          <ChapterNumber>Chapter 14</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_14</ChapterDOI>
          <ChapterSequenceNumber>14</ChapterSequenceNumber>
          <ChapterTitle Language="En">Platinum Agents in Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>153</ChapterFirstPage>
          <ChapterLastPage>161</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>3</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Ashley</GivenName>
                <FamilyName>Brick</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Junyang</GivenName>
                <FamilyName>Niu</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Jiaoti</GivenName>
                <FamilyName>Huang</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff1_14" CorrespondingAffiliationID="Aff1_14">
              <AuthorName DisplayOrder="Western">
                <GivenName>William</GivenName>
                <GivenName>K.</GivenName>
                <FamilyName>Oh</FamilyName>
              </AuthorName>
              <Contact>
                <Email>william.oh@mssm.edu</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_14">
              <OrgDivision>Division of Hematology and Medical Oncology</OrgDivision>
              <OrgName>Dana-Farber Cancer Institute</OrgName>
              <OrgAddress>
                <City>New York</City>
                <Postcode>10029</Postcode>
                <State>NY</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_14" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">The standard first-line treatment for metastatic castration-resistant prostate cancer (CRPC) is docetaxel chemotherapy. Platinum drugs, including cisplatin and carboplatin, when used as single agents and in combinations, have shown a moderate response in metastatic CRPC patients, as both first- and second-line treatment. Furthermore, the relationship between neuroendocrine differentiation and castration-resistant disease progression suggests that there may be a possible role for platinum agents. Newer platinum analogs, including picoplatin, oxaliplatin, and satraplatin have been recently studied in CRPC. Though a Phase III trial demonstrated a progression-free survival benefit favoring satraplatin plus prednisone versus prednisone alone, no overall survival benefit was demonstrated in the second-line setting. Further trials will be needed to demonstrate a clear role for platinum agents in CRPC.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Carboplatin</Keyword>
            <Keyword>Neuroendocrine</Keyword>
            <Keyword>Castration-resistant</Keyword>
            <Keyword>Chemotherapy</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Docetaxel is currently the standard first-line chemotherapy for patients with metastatic castration-resistant prostate cancer (CRPC) [<CitationRef CitationID="CR1_14">1</CitationRef>, <CitationRef CitationID="CR2_14">2</CitationRef>]. However, after progression on docetaxel chemotherapy, there is no uniformly accepted second-line chemotherapy [<CitationRef CitationID="CR3_14">3</CitationRef>]. Recent trials have suggested that treatment with platinum drugs alone or in combination with taxanes may have important clinical activity [<CitationRef CitationID="CR4_14">4</CitationRef>]. Although it was previously believed that platinum drugs had little activity in CRPC, these recent studies, which used palliation as well as PSA endpoints, have demonstrated clinical benefits. Also, newer and more potent platinum analogues, such as satraplatin and picoplatin, have shown activity in CRPC and have been studied in recent clinical trials [<CitationRef CitationID="CR5_14">5</CitationRef>–<CitationRef CitationID="CR7_14">7</CitationRef>].</Para>
            <Para TextBreak="No">Today it is not clear how prostate cancer (CaP) advances to a castration-resistant state. One mechanism proposes that neuroendocrine (NE) differentiation is a contributing factor to the progression towards CRPC [<CitationRef CitationID="CR8_14">8</CitationRef>]. Recent research has better elucidated the biology of NE differentiation in prostate cancer. Although several studies have focused on the relationship between NE differentiation and activity of platinum chemotherapy, it remains unclear if there is a “platinum-sensitive” subtype of CaP that can be biologically determined.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Neuroendocrine Differentiation in Prostate Cancer</Heading>
            <Para TextBreak="No">NE differentiation is a consistent histologic feature of prostate cancer, making it a unique tumor among all epithelial malignancies [<CitationRef CitationID="CR9_14">9</CitationRef>]. However, the concept of NE differentiation has caused confusion among clinicians and basic researchers alike, which needs to be more clearly defined.</Para>
            <Para TextBreak="No">Epithelial components of the normal prostate include luminal secretory cells, basal cells, and a third minor component of NE cells. NE cells have neuron-like morphology ultrastructurally and endocrine function including the secretion of biogenic amines and neuropeptides. They are widely distributed in the normal prostate with only an occasional cell per gland or duct but cannot be easily distinguished from surrounding cell on H&amp;E-stained sections under light microscopy. Immunohistochemical staining for NE markers such as chromogranin A, synaptophysin, and neuron-specific enolase (NSE) is a sensitive and specific method to identify such cells in formalin-fixed, paraffin-embedded tissue sections. The function of NE cells in normal prostate is unclear. NE cells are also present in prostate cancer. Very rarely, a prostate cancer is composed entirely of NE tumor cells. Depending on the morphologic features of tumor cells, the amount of necrosis, and the frequency of mitotic figures, such tumors may be classified as small cell carcinoma [<CitationRef CitationID="CR10_14">10</CitationRef>, <CitationRef CitationID="CR11_14">11</CitationRef>], large cell neuroendocrine carcinoma [<CitationRef CitationID="CR12_14">12</CitationRef>], or carcinoid tumor [<CitationRef CitationID="CR13_14">13</CitationRef>–<CitationRef CitationID="CR15_14">15</CitationRef>]. Such pure neuroendocrine tumors are subtypes of prostatic epithelial malignancies and comprise no more than 1% of all tumors of the prostate. The vast majority of prostate cancers are adenocarcinomas with tumor cells showing luminal secretory cell features including the expression of androgen receptor (AR) and secretion of PSA. NE differentiation of prostate cancer commonly refers to the presence of rare individual NE cells or small nests of NE cells scattered among the more abundant luminal secretory-type cancer cells in conventional adenocarcinomas [<CitationRef CitationID="CR16_14">16</CitationRef>, <CitationRef CitationID="CR17_14">17</CitationRef>]. By this definition, all adenocarcinomas of the prostate demonstrate some degree of NE differentiation [<CitationRef CitationID="CR18_14">18</CitationRef>].</Para>
            <Para TextBreak="No">NE tumor cells, unlike the non-NE secretory type tumor cells of CaP, do not express androgen receptor (AR) and are likely androgen-independent. It is therefore hypothesized that while hormonal therapy causes apoptosis of the AR-positive (androgen-dependent) secretory-type tumor cells, it will not affect NE tumor cells and may actually enrich the NE tumor cell population. The NE cells that survive hormonal therapy may, through secretion of their products, establish paracrine networks to stimulate androgen-independent proliferation of the secretory type tumor cells, leading to tumor recurrence. Therefore, the cellular heterogeneity of prostate cancer may explain the inability of hormonal therapy to eliminate all cancer cells and contribute to its eventual failure in most patients. Many studies suggest that ADT may induce NE differentiation and the latter contributes to the emergence of CRPC. For instance, NE differentiation is increased in high-grade and high-stage [<CitationRef CitationID="CR23_14">19</CitationRef>] localized tumors. Also, it has been shown that levels of circulating chromogranin A (CgA), a product of prostate NE cells, are higher in prostate cancer patients than in patients with benign prostatic conditions. In patients with CaP, serum levels of CgA correlate with both the clinical stage of disease, as well as with the degree to which the cancer has become hormone refractory [<CitationRef CitationID="CR24_14">20</CitationRef>]. Positive staining for CgA by immunohistochemistry of tumor tissue is an independent predictor of cancer progression in well and moderately differentiated prostate cancers [<CitationRef CitationID="CR25_14">21</CitationRef>]. In castration-resistant disease, elevated serum CgA is a significant predictor of poor prognosis, independent of serum PSA and other prognostic factors [<CitationRef CitationID="CR26_14">22</CitationRef>, <CitationRef CitationID="CR27_14">23</CitationRef>]. Finally, in a gene expression profiling experiment of primary prostate cancers, Singh et al. showed that CgA is one of five genes that correlate strongly with the Gleason score and that this five gene expression model alone accurately predicts the outcome following radical prostatectomy [<CitationRef CitationID="CR28_14">24</CitationRef>].</Para>
            <Para TextBreak="No">The relationship of NE differentiation in prostate cancer with chemotherapy is not as well studied. Unlike the non-NE secretory type tumor cells that show proliferative activity, NE tumor cells are normally quiescent, and this may make them resistant to chemotherapeutic agents that target fast-proliferating tumor cells. Interestingly, it has been shown that higher chromogranin A level in patients with CRPC correlated with response to chemotherapy (paclitaxel and carboplatin or mitoxantrone), but not with overall survival [<CitationRef CitationID="CR29_14">25</CitationRef>]. Patients with a PSA response after chemotherapy more commonly had a CgA decrease of 25% or greater than those without a response [<CitationRef CitationID="CR29_14">25</CitationRef>].</Para>
            <Para TextBreak="No">The function of NE differentiation has been extensively studied in in vitro and in vivo assays. NE cells secrete biogenic amines, neuropeptides, and cytokines [<CitationRef CitationID="CR30_14">26</CitationRef>] and the non-NE tumor cells express receptors for many of NE cell products [<CitationRef CitationID="CR31_14">27</CitationRef>–<CitationRef CitationID="CR37_14">33</CitationRef>]. In vitro, some NE cell products stimulate proliferation of prostate cancer cells. For instance, interleukin-8 (IL-8), an angiogenic and mitogenic factor for many tumors including CaP, promotes proliferation of prostate cancer cells in the absence of androgen in an in vitro assay [<CitationRef CitationID="CR38_14">34</CitationRef>]. Tissue studies have similarly shown that NE cells in prostate cancer produce IL-8 and non-NE tumor cells express increased levels of the IL-8 receptor CXCR1 [<CitationRef CitationID="CR39_14">35</CitationRef>], suggesting that NE differentiation may be one of the factors contributing to the progression of CaP in a paracrine fashion [<CitationRef CitationID="CR40_14">36</CitationRef>–<CitationRef CitationID="CR42_14">38</CitationRef>]. Deeble et al. showed that LNCaP cells could be induced to show NE phenotype by constitutive expression of an activated form of the cyclic AMP-dependent protein kinase A catalytic subunit. Such NE-like cells could induce proliferation of LNCaP cells in vitro and xenograft tumors in vivo, particularly in castrated hosts [<CitationRef CitationID="CR43_14">39</CitationRef>]. In the CWR22 xenograft tumor model, there was a significant increase in the number of NE cells after castration that preceded the increase in tumor cell proliferation [<CitationRef CitationID="CR44_14">40</CitationRef>]. In the transgenic adenocarcinoma of the mouse prostate (TRAMP) tumor model and the PTEN knockout model, recurrent tumors after castration were also associated with increased NE differentiation [<CitationRef CitationID="CR45_14">41</CitationRef>, <CitationRef CitationID="CR46_14">42</CitationRef>]. LNCaP xenograft tumors do not normally survive in castrated hosts, but an allograft mouse NE tumor (NE-10) implanted on the opposite flank could support LNCaP xenograft tumor in castrated mice, providing strong evidence for the function of NE differentiation in androgen-independent proliferation of prostate cancer [<CitationRef CitationID="CR47_14">43</CitationRef>]. In an uncastrated host, the same NE cells appear to enhance migration and invasion of LNCaP tumor cells [<CitationRef CitationID="CR48_14">44</CitationRef>].</Para>
            <Para TextBreak="No">As NE tumor cells likely represent the androgen-independent subpopulation of CaP cells and may be responsible for tumor recurrence, targeting NE cells in CRPC may thus provide a novel approach to treat this disease. It is known that platinum has activity against cancers with NE differentiation. Together with etoposide or irinotecan, it generates the highest response rates in small cell lung cancer and is the established first-line treatment option for this disease [<CitationRef CitationID="CR49_14">45</CitationRef>]. Pure small cell carcinoma of the prostate is a rare disease and is generally managed similarly to other extrapulmonary small cell carcinomas. Since most of these patients present with metastatic disease at diagnosis, treatment usually consists of cisplatin and etoposide. In those with more localized disease, treatment directed at the prostate with surgery or more commonly radiotherapy can be considered.</Para>
            <Para TextBreak="No">If the importance of NE differentiation of prostate cancer is confirmed over time, use of chemotherapies that specifically target NE cells may be a reasonable added option in the armamentarium of CaP treatment and it may provide a rationale for combining platinum drugs with others directed more specifically at the non-NE epithelial cancer cells.</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>First-Line Platinum Chemotherapy for Prostate Cancer</Heading>
            <Section2 ID="Sec4">
              <Heading>Single-Agent Cisplatin and Carboplatin</Heading>
              <Para TextBreak="No">Platinum drugs were studied both as single therapies as well as in combination with taxane chemotherapy (Table <InternalRef RefID="Tab1">14.1</InternalRef>). Cisplatin was the most common treatment in the time period before PSA evaluation. Twenty-five patients were treated with an every 3 weeks regimen of 50–75 mg/m<Superscript>2</Superscript> of single-agent cisplatin in 1979 by Yagoda et al. [<CitationRef CitationID="CR50_14">46</CitationRef>]. Twelve percent of patients achieved a partial response, and evaluation with the National Prostate Cancer Project criteria reported 24 patients with stable disease. A later study treated 18 patients with 50 mg/m<Superscript>2</Superscript> every 3 weeks with no patients achieving measurable response, leading investigators to conclude that the treatment course was not active [<CitationRef CitationID="CR51_14">47</CitationRef>]. In a 1993 review article, Yagoda and Petrylak reported an overall 12% partial response rate for 209 patients treated with cisplatin [<CitationRef CitationID="CR52_14">48</CitationRef>]. Further examination of both trials with cisplatin every 3 weeks indicated that treatment dose was low and activity level was a reflection of patient selection. This conclusion is based on other studies with higher treatment doses (1 mg/kg per week) for 6 weeks with responses visible in many sites including liver, lung, lymph nodes, and bone.<Table Float="Yes" ID="Tab1">
                  <Caption Language="En">
                    <CaptionNumber>Table 14.1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Single agent cisplatin and carboplatin in CRPC</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="5">
                    <colspec colname="c1" colnum="1"/>
                    <colspec colname="c2" colnum="2"/>
                    <colspec colname="c3" colnum="3"/>
                    <colspec colname="c4" colnum="4"/>
                    <colspec colname="c5" colnum="5"/>
                    <thead>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Author, year</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>
                            <Emphasis Type="Italic">N</Emphasis>
                          </SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>PSA response rate (%)</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Measurable response rate (%)</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Duration of response, median (months)</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry nameend="c5" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Italic">Cisplatin</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Merrin, 1978</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>21</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>–</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>43</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>5.8</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Merrin, 1979</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>45</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>–</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>29</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>6</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Merrin, 1979</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>54</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>–</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>31.4</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>7</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Yagoda, 1979</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>25</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>–</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>12</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>2.5</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Qazi, 1983</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>18</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>–</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>0</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>–</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Moore, 1986</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>29</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>–</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>10</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>8</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry nameend="c5" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Italic">Carboplatin</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Trump, 1990</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>29</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>–</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>20</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>3</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Canobbio, 1993</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>25</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>12</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>17</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>7</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Miglietta, 1995</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>40</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>28</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>17</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>6.6</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Jungi, 1998</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>27</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>8</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>6</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>NR</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Castagneto, 2006</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>27</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>27</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>NR</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>NR</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                </Table>
              </Para>
              <Para TextBreak="No">Carboplatin is a second-generation platinum chemotherapy with a different toxicity profile than cisplatin. The Eastern Cooperative Oncology Group (ECOG) treated 29 CPRC patients with 250–400 mg/m<Superscript>2</Superscript> carboplatin depending on renal function and previous radiation. Results show that one out of five (20%) patients with bidimensionally measurable disease achieved a partial response, 1 out of 24 patients with an abnormal bone scan had ≥50% regression in the number of sites with abnormal tracer uptake, and 3 out of 24 patients experienced clinical benefit [<CitationRef CitationID="CR53_14">49</CitationRef>]. Although investigators deemed carboplatin’s activity insignificant, it is noted that compared with modern standards, the treatment dose was low and was not administered using the current area under the curve (AUC) method. Furthermore, the patient population included those with bone metastases, unlike prior cisplatin studies, and was therefore unable to be evaluated by standard, cross-sectional imaging techniques that were developed at that time.</Para>
              <Para TextBreak="No">In the post-PSA era, four clinical trials with weekly carboplatin all showed activity when evaluated by clinical benefit, measurable response, or PSA decline. Canobbio et al. calculated a 17% response rate when combining both measurable and evaluable disease (using PSA and prostatic acid phosphatase) [<CitationRef CitationID="CR54_14">50</CitationRef>]. Patients were treated with a weekly 150 mg/m<Superscript>2</Superscript> carboplatin dose, increasing dose intensity after treatments every 3 or 4 weeks. Miglietta et al. performed a second 35 patient study with an equal weekly treatment schedule. Ten patients (28%) had a PSA decline ≥50%, and the mean response duration was 6.6 months [<CitationRef CitationID="CR55_14">51</CitationRef>]. Another study by Jungi et al. treated 27 CRPC patients with 400 mg/m<Superscript>2</Superscript> carboplatin every 28 days. Thirteen out of 27 patients exhibited a decrease in pain, an improved performance status, and stabilization of metastases, resulting in a 48% clinical benefit response rate [<CitationRef CitationID="CR56_14">52</CitationRef>]. Moreover, 2 out of 24 evaluable patients (8%) showed a PSA response though investigators found no clear link between clinical benefit and PSA decline. At the 2006 Prostate Cancer Symposium, Castagneto et al. reported a study that evaluated 27 CRPC patients treated with 150 mg/m<Superscript>2</Superscript> weekly for 3 or 4 weeks. PSA decline ≥50% was achieved by 26.9% of patients after treatment [<CitationRef CitationID="CR57_14">53</CitationRef>]. These trials clearly suggest that carboplatin has definite though moderate activity in CRPC even with various weekly or monthly treatment schedules. No recent trials of carboplatin alone, using AUC dosing, have been reported.</Para>
            </Section2>
            <Section2 ID="Sec5">
              <Heading>Multiagent Regimens with Cisplatin and Carboplatin</Heading>
              <Para TextBreak="No">Cisplatin in combination with other drugs is active in CRPC. A multiagent Phase II trial of cisplatin and doxorubicin reported clinical benefit in 24% of patients along with measurable improvement in prostatic acid phosphatase in 21% of patients [<CitationRef CitationID="CR58_14">54</CitationRef>]. Other trials evaluated cisplatin with the following agents: doxorubicin plus 5-flourouracil [<CitationRef CitationID="CR59_14">55</CitationRef>], strontium-89 [<CitationRef CitationID="CR60_14">56</CitationRef>], etopside plus pirarubicin [<CitationRef CitationID="CR61_14">57</CitationRef>], mitoxantrone [<CitationRef CitationID="CR62_14">58</CitationRef>], estramustine plus etoposide [<CitationRef CitationID="CR63_14">59</CitationRef>], and calcitriol plus dexamethasone [<CitationRef CitationID="CR64_14">60</CitationRef>].</Para>
              <Para TextBreak="No">Comparison between Strontium-89 (<Superscript>89</Superscript>Sr) with and without cisplatin in a randomized Phase III trial showed mixed results. Seventy CRPC patients with painful bone metastases were evaluated with study endpoints of palliation of bone pain at 2 months, onset of new bone pain, progression of bone metastases, and survival. Cisplatin was infused three times in 11 days up to a total dose of 50 mg/m<Superscript>2</Superscript> before and after <Superscript>89</Superscript>Sr. Pain improvement at 2 months was reported to be 91% for combination therapy and 63% for <Superscript>89</Superscript>Sr alone. Bone metastases progression was 64% versus 27% favoring the single agent. There were no significant differences in the onset of new bone metastases or survival [<CitationRef CitationID="CR65_14">61</CitationRef>].</Para>
              <Para TextBreak="No">Docetaxel now serves as the standard upon which other agents are added. A number of clinical trials recently combined carboplatin with a taxane (docetaxel or paclitaxel) and estramustine and reported encouraging results (Table <InternalRef RefID="Tab2">14.2</InternalRef>) [<CitationRef CitationID="CR66_14">62</CitationRef>–<CitationRef CitationID="CR72_14">68</CitationRef>]. Phase II trials reported PSA declines ≥50% in 60–100% of CRPC patients and objective response rates from 45 to 65% in the cohort of patients with measurable disease. The results further suggest that carboplatin may have success as a second-line therapy for some CRPC patients. However, it should be noted that patients were highly selected for these Phase II trials, and therefore, results may vary in a real world population.<Table Float="Yes" ID="Tab2">
                  <Caption Language="En">
                    <CaptionNumber>Table 14.2</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Recent trials of estramustine, platinum, and taxane chemotherapy</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="6">
                    <colspec colname="c1" colnum="1"/>
                    <colspec colname="c2" colnum="2"/>
                    <colspec colname="c3" colnum="3"/>
                    <colspec colname="c4" colnum="4"/>
                    <colspec colname="c5" colnum="5"/>
                    <colspec colname="c6" colnum="6"/>
                    <thead>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Author, year</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Phase</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Regimen</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Number of patients</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>PSA response rate</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Measurable response rate</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Kelly, 2001</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Paclitaxel/estramustine/carboplatin</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>56</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>67</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>45</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Urakami, 2002</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Paclitaxel/estramustine/carboplatin</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>32</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>100</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>61</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Solit, 2003</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Paclitaxel/estramustine/carboplatin</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>30</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>60</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>65</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Oh, 2004</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Docetaxel/estramustine/carboplatin</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>40</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>68</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>52</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Oh, 2005</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>I/II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Docetaxel/estramustine/carboplatin</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>30</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>63<Superscript>a</Superscript>
                          </SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>24<Superscript>a</Superscript>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Berry, 2006</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Paclitaxel/estramustine/carboplatin</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>84</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>61</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>50<Superscript>b</Superscript>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Kikuno, 2006</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Docetaxel/estramustine/carboplatin</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>40</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>95</SimplePara>
                        </entry>
                        <entry colname="c6"/>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Breitz, 2008</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Picoplatin/docetaxel</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>30</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>59</SimplePara>
                        </entry>
                        <entry colname="c6"/>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Ross, 2008</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Carboplatin/docetaxel</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>34</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>18</SimplePara>
                        </entry>
                        <entry colname="c6"/>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>
                      <Superscript>a</Superscript>At the recommended Phase II dose, the PSA response rate was 75% in 12 patients and measurable responses were seen in two of five (40%) patients
</SimplePara>
                    <SimplePara>
                      <Superscript>b</Superscript>Reported as a pooled endpoint of measurable and/or PSA response</SimplePara>
                  </tfooter>
                </Table>
              </Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>New Platinum Drugs</Heading>
              <Para TextBreak="No">Recently, various platinum analogs have been tested in the clinical trial setting with both CRPC as well as many other cancers, and a recent comprehensive summary of novel platinum compounds has been published. Oxaliplatin, a platinum analog with a favorable toxicity profile, has shown positive results in cisplatin-resistant cell lines. Droz et al. evaluated the activity of oxaliplatin with and without 5-fluorouracil in 54 CRPC patients in a randomized, multicenter Phase II study. PSA declines were reported in 11 and 19% of patients in each arm, even with more than 50% of the patient population already treated with chemotherapy (including cisplatin) [<CitationRef CitationID="CR73_14">69</CitationRef>].</Para>
              <Para TextBreak="No">Picoplatin is a new platinum therapy developed to overcome platinum resistance. A Phase I study conducted by Breitz et al. showed efficacy in CRPC patients treated with a combination of 120 mg/m<Superscript>2</Superscript> picoplatin and 75 mg/m<Superscript>2</Superscript> docetaxel with prednisone. Nineteen out of 32 evaluable patients (59%) reported a PSA response. At ASCO 2008, Breitz et al. presented a Phase II study which enrolled 30 CRPC on a treatment regimen of 120 mg/m<Superscript>2</Superscript> picoplatin and 75 mg/m<Superscript>2</Superscript> docetaxel every 3 weeks plus prednisone 5 mg PO bid. Current data report that 59% of evaluable patients achieved a PSA response of &gt;50% decrease for at least 4 weeks indicating that platinum chemotherapy in combination with current therapy may have potential benefit for CRPC patients [<CitationRef CitationID="CR6_14">6</CitationRef>].</Para>
              <Para TextBreak="No">Platinum drugs have been tested in other cisplatin-resistant cancers including ovarian and lung cancer. Platinum compound ZD-0473 reported activity in both ovarian and lung cancer cell lines with moderate response rates achieved in both platinum-resistant cancers [<CitationRef CitationID="CR73_14">69</CitationRef>]. Additionally, lobaplatin has also been found to be of benefit in cisplatin-resistant cancer cell lines [<CitationRef CitationID="CR74_14">70</CitationRef>].</Para>
              <Para TextBreak="No">Although recent trials have targeted novel drugs in the hope of isolating a standard for second-line therapy, alternative approaches to improving platinum chemotherapy include improving the delivery of the drug to the cancer itself.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>Platinum Drugs as Second-Line Therapy for CRPC</Heading>
            <Para TextBreak="No">With no single standard of care for second-line therapy, patient participation in clinical trials remains a necessary priority [<CitationRef CitationID="CR3_14">3</CitationRef>]. Platinum drugs are currently in clinical development for treatment of CRPC for patients who progressed on docetaxel. Satraplatin and carboplatin represent two platinum analogs that have been tested recently in clinical trials.</Para>
            <Para TextBreak="No">In the randomized Phase III data from the SPARC (Satraplatin and Prednisone against Refractory Cancer) trial, 950 metastatic CRPC patients were enrolled to evaluate second-line satraplatin plus prednisone versus prednisone alone [<CitationRef CitationID="CR73_14">73</CitationRef>]. Patients were treated 2:1 to satraplatin 80 mg/m<Superscript>2</Superscript> days 1–5 for 5 weeks with 5 mg prednisone twice daily or to prednisone alone. Patients on satraplatin plus prednisone demonstrated a 42% improvement in progression-free survival (PFS) when compared to prednisone alone, as well as a prolonged time to pain progression and a higher PSA response rate. After 6 months, PFS was reported to be 30 and 17% for the satraplatin plus prednisone arm and the prednisone alone arm, respectively. At 12 months, satraplatin plus prednisone continued to show an increase in the percentage of PFS at 17% versus 7% in prednisone alone. These improvements, however, did not translate into a benefit in overall survival, and satraplatin did not receive approval by the Food and Drug Administration.</Para>
            <Para TextBreak="No">In a continued effort to expand the second-line therapy options in an environment of limited choices, Ross et al. enrolled 34 patients who progressed on docetaxel in a prospective, multicenter trial of docetaxel 60 mg/m<Superscript>2</Superscript> plus carboplatin AUC (4) every 3 weeks. Six out of 34 patients achieved a partial response according to PSA criteria (decrease in ≥50% in serum PSA), and ten patients had stable disease, with three out of ten remaining stable for ≥3 months [<CitationRef CitationID="CR75_14">71</CitationRef>]. Although not statistically significant, results showed that patients with a serum PSA drop ≥50% when treated initially with docetaxel alone were more likely to respond to the combination of docetaxel plus carboplatin. Of the CRPC patients with progressive disease during or shortly after initial treatment with single agent docetaxel, adding carboplatin resulted in PSA declines ≥50% in 18% of patients, and median PFS was 3 months with median response duration of 5.7 months. Further analysis included measurements of the circulating markers, chromagranin A (CgA) and neuron-specific enolase (NSE), from serum samples, showing a trend toward improved PSA response rate in patients with a lower CgA level at baseline; however, the data was not statistically significant.</Para>
            <Para TextBreak="No">In 2007, Nakabayashi et al. published a retrospective study evaluating docetaxel/carboplatin as first- and second-line chemotherapy for CRPC patients [<CitationRef CitationID="CR76_14">72</CitationRef>]. Study cohort included patients treated with first-line docetaxel/carboplatin plus estramustine as well as second-line docetaxel/carboplatin alone. The study evaluated 54 patients, and 24 out of them received first-line 140 mg estramustine three times daily plus carboplatin every 3–4 weeks and 20–70 mg/m<Superscript>2</Superscript> docetaxel. The remaining 30 patients received second-line 50–70 mg/m<Superscript>2</Superscript> docetaxel and carboplatin every 3–4 weeks. Results showed PSA declines of ≥50% in 88 and 20%, respectively, as well as a median overall survival of 17.7 and 14.9 months, respectively. Results suggest that adding carboplatin to traditional docetaxel treatment as second-line therapy positively influences activity in 20% of CRPC patients.</Para>
          </Section1>
          <Section1 ID="Sec8" Type="Conclusion">
            <Heading>Conclusion</Heading>
            <Para TextBreak="No">Platinum chemotherapy has been a part of treatment regimens for decades in many cancers including lung, ovarian, and testicular carcinomas. Unlike in these diseases, in which efficacy of platinum chemotherapy is clearly proven, its activity in prostate cancer remains less certain. Pre-PSA era trials evaluating cisplatin and carboplatin as single and as part of multiagent regimens did not demonstrate clear clinical benefit, though one can argue that the rules determining response in the 1980s and 1990s were ineffective. Carboplatin trials in the mid-1990s showed palliative benefit and PSA declines which led to further evaluation. In recent years, multiple trials have combined carboplatin with estramustine and a taxane and shown evidence of high PSA and measurable response rates. However, the question still remains as to the extent to which carboplatin influences PFS or overall survival in CRPC patients.</Para>
            <Para TextBreak="No">There is strong support for the consideration of platinum chemotherapy in the management of CRPC. Although docetaxel chemotherapy remains the standard of care for initial treatment of patients with metastatic prostate cancer, platinum chemotherapy alone or in combination with other drugs may have meaningful clinical benefit as second-line therapy for CRPC patients. The SPARC trial showed improvements in PFS and pain response, though overall survival was not affected.</Para>
            <Para TextBreak="No">The possibility for specific subtypes of patients with CRPC achieving a greater response to platinum analogs than others requires continued efforts to define these distinct phenotypes.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_14.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_14">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1513</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470214</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa041318</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_14">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1502</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470213</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa040720</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_14">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Rosenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">What is the current status of second-line chemotherapy for castration-resistant prostate cancer?</ArticleTitle>
                <JournalTitle>Nat Clin Pract Urol</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>650</FirstPage>
                <LastPage>1</LastPage>
                <Occurrence Type="PID">
                  <Handle>18936787</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ncpuro1232</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhsVCku7vK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rosenberg JE, Oh WK. What is the current status of second-line chemotherapy for castration-resistant prostate cancer? Nat Clin Pract Urol 2008;5(12):650–1.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_14">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Tay</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>109</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>477</FirstPage>
                <LastPage>86</LastPage>
                <Occurrence Type="PID">
                  <Handle>17186531</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.22439</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXitV2itr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Oh WK, Tay M, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007;109(3):477–86.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_14">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CN</Initials>
                  <FamilyName>Sternberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Whelan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Hetherington</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Oncology</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>2</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15741753</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1159/000084201</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjslCgtLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68:2–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_14">
              <CitationNumber>6</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>HB</Initials>
                  <FamilyName>Breitz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Roman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Karlov</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <BookTitle>A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naïve patients with metastatic hormone refractory prostate cancer (CRPC). J Clin Oncol</BookTitle>
                <BibComments>26 (May 20 Suppl; abstr 5153)</BibComments>
              </BibBook>
              <BibUnstructured>Breitz HB, Roman LA, Karlov PA, et al. A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naïve patients with metastatic hormone refractory prostate cancer (CRPC). J Clin Oncol 2008; 26 (May 20 Suppl; abstr 5153).</BibUnstructured>
            </Citation>
            <Citation ID="CR7_14">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>McKeage</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">New-generation platinum drugs in the treatment of cisplatin-resistant cancers</ArticleTitle>
                <JournalTitle>Expert Opin Investig Drugs</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>1033</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>16050795</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1517/13543784.14.8.1033</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmvFelsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>McKeage MJ. New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs 2005;14:1033–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_14">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Sant’Agnese</FamilyName>
                  <Particle>di</Particle>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Neuroendocrine differentiation in human prostatic carcinoma</ArticleTitle>
                <JournalTitle>Hum Pathol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>287</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>1313390</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0046-8177(92)90110-O</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>di Sant’Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23:287–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_14">
              <CitationNumber>9</CitationNumber>
              <BibChapter>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>diSant’Agnese</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ChapterTitle Language="En">Neuroendocrine differentiation in prostate cancer: an overview</ChapterTitle>
                <BibEditorName>
                  <Initials>S</Initials>
                  <FamilyName>Lamberts</FamilyName>
                </BibEditorName>
                <Eds/>
                <BookTitle>Advances in Oncology: The Expanding Role of Octreotide</BookTitle>
                <PublisherName>BioScientifica Ltd</PublisherName>
                <PublisherLocation>Bristol</PublisherLocation>
                <FirstPage>243</FirstPage>
                <LastPage>62</LastPage>
              </BibChapter>
              <BibUnstructured>Huang J, diSant’Agnese PA. Neuroendocrine differentiation in prostate cancer: an overview. In: Lamberts S, editor. Advances in Oncology: The Expanding Role of Octreotide. Bristol: BioScientifica Ltd; 2002. p. 243–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_14">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Yao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Madeb</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Bourne</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Small cell carcinoma of the prostate: an immunohistochemical study</ArticleTitle>
                <JournalTitle>Am J Surg Pathol</JournalTitle>
                <VolumeID>30</VolumeID>
                <FirstPage>705</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>16723847</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00000478-200606000-00005</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006;30:705–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_14">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases</ArticleTitle>
                <JournalTitle>Am J Surg Pathol</JournalTitle>
                <VolumeID>32</VolumeID>
                <FirstPage>65</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>18162772</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/PAS.0b013e318058a96b</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wang W, Epstein JI. Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_14">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Evans</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Humphrey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Belani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TH</Initials>
                  <FamilyName>Kwast</FamilyName>
                  <Particle>van der</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Srigley</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer</ArticleTitle>
                <JournalTitle>Am J Surg Pathol</JournalTitle>
                <VolumeID>30</VolumeID>
                <FirstPage>684</FirstPage>
                <LastPage>93</LastPage>
                <Occurrence Type="PID">
                  <Handle>16723845</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00000478-200606000-00003</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006;30:684–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_14">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Lim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Hsieh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Primary carcinoid tumor of prostate presenting with bone marrow metastases</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>174</FirstPage>
                <Occurrence Type="PID">
                  <Handle>15667891</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2004.07.010</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lim KH, Huang MJ, Yang S, Hsieh RK, Lin J. Primary carcinoid tumor of prostate presenting with bone marrow metastases. Urology 2005;65:174.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_14">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Reyes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Moran</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate</ArticleTitle>
                <JournalTitle>Arch Pathol Lab Med</JournalTitle>
                <VolumeID>128</VolumeID>
                <FirstPage>e166</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>15578903</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Reyes A, Moran CA. Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. Arch Pathol Lab Med 2004;128:e166–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_14">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Ghannoum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>DeLellis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Shin</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report</ArticleTitle>
                <JournalTitle>Int J Surg Pathol</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>167</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>15173926</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1177/106689690401200214</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ghannoum JE, DeLellis RA, Shin SJ. Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report. Int J Surg Pathol 2004;12:167–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_14">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Abrahamsson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Falkmer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Falt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Grimelius</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an “endocrine marker”</ArticleTitle>
                <JournalTitle>Pathol Res Pract</JournalTitle>
                <VolumeID>185</VolumeID>
                <FirstPage>373</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>2813190</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0344-0338(89)80016-0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3c%2Fks1alsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an “endocrine marker”. Pathol Res Pract 1989;185:373–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_14">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Abrahamsson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LB</Initials>
                  <FamilyName>Wadstrom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Alumets</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Falkmer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Grimelius</FamilyName>
                </BibAuthorName>
                <Year>1987</Year>
                <ArticleTitle Language="En">Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate</ArticleTitle>
                <JournalTitle>Pathol Res Pract</JournalTitle>
                <VolumeID>182</VolumeID>
                <FirstPage>298</FirstPage>
                <LastPage>307</LastPage>
                <Occurrence Type="PID">
                  <Handle>2442732</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0344-0338(87)80065-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2szhslantQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 1987;182:298–307.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_14">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Yao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Sant’agnese</FamilyName>
                  <Particle>di</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Q</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Bourne</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Na</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Immunohistochemical characterization of neuroendocrine cells in prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>1399</FirstPage>
                <LastPage>406</LastPage>
                <Occurrence Type="PID">
                  <Handle>16865726</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20434</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtVGitr%2FN</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huang J, Yao JL, di Sant’agnese PA, Yang Q, Bourne PA, Na Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 2006;66:1399–406.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_14">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Puccetti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CT</Initials>
                  <FamilyName>Supuran</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PP</Initials>
                  <FamilyName>Fasolo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>48</VolumeID>
                <FirstPage>215</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>15992991</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2005.03.018</Handle>
                </Occurrence>
                <BibComments>discussion 21–3</BibComments>
              </BibArticle>
              <BibUnstructured>Puccetti L, Supuran CT, Fasolo PP, et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur Urol 2005;48:215–21; discussion 21–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_14">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Berruti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Dogliotti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mosca</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Circulating neuroendocrine markers in patients with prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>88</VolumeID>
                <FirstPage>2590</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10861438</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(20000601)88:11&lt;2590::AID-CNCR23&gt;3.0.CO;2-D</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3cvisFyrug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_14">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>VE</Initials>
                  <FamilyName>Theodoropoulos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Tsigka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mihalopoulou</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>897</FirstPage>
                <LastPage>902</LastPage>
                <Occurrence Type="PID">
                  <Handle>16230178</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2005.04.064</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD2MrlsV2jsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Theodoropoulos VE, Tsigka A, Mihalopoulou A, et al. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology 2005;66:897–902.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_14">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>George</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Prognostic significance of plasma chromogranin A levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>386</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>16098367</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2005.03.040</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taplin ME, George DJ, Halabi S, et al. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 2005;66:386–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_14">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Berruti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mosca</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Tucci</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease</ArticleTitle>
                <JournalTitle>Endocr Relat Cancer</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>109</FirstPage>
                <LastPage>17</LastPage>
                <Occurrence Type="PID">
                  <Handle>15788643</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1677/erc.1.00876</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjsV2lsb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005;12:109–17.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_14">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Singh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PG</Initials>
                  <FamilyName>Febbo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Gene expression correlates of clinical prostate cancer behavior</ArticleTitle>
                <JournalTitle>Cancer Cell</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>203</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12086878</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1535-6108(02)00030-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XivVegsbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_14">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Cabrespine</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Guy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Gachon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Cure</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Chollet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JO</Initials>
                  <FamilyName>Bay</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Circulating chromogranin A and hormone refractory prostate cancer chemotherapy</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>175</VolumeID>
                <FirstPage>1347</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>16515996</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)00640-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XjtlWkurg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cabrespine A, Guy L, Gachon F, Cure H, Chollet P, Bay JO. Circulating chromogranin A and hormone refractory prostate cancer chemotherapy. J Urol 2006;175:1347–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_14">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Abdul</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PE</Initials>
                  <FamilyName>Anezinis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Logothetis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Hoosein</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>1215</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>8074475</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXmslaktbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994;14:1215–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_14">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Dizeyi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bjartell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Nilsson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>328</FirstPage>
                <LastPage>36</LastPage>
                <Occurrence Type="PID">
                  <Handle>15042609</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.10374</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkt12is7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dizeyi N, Bjartell A, Nilsson E, et al. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004;59:328–36.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_14">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AG</Initials>
                  <FamilyName>Aprikian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Han</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Chevalier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Bazinet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Viallet</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells</ArticleTitle>
                <JournalTitle>J Mol Endocrinol</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>297</FirstPage>
                <LastPage>306</LastPage>
                <Occurrence Type="PID">
                  <Handle>8782088</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1677/jme.0.0160297</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XjslWgsLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 1996;16:297–306.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_14">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Reubi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Wenger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schmuckli-Maurer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Schaer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Gugger</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6–14)</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>1139</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>11948125</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XjsF2lt7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6–14). Clin Cancer Res 2002;8:1139–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_14">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Seethalakshmi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Mitra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Dobner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Menon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Carraway</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>31</VolumeID>
                <FirstPage>183</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>9167771</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0045(19970515)31:3&lt;183::AID-PROS7&gt;3.0.CO;2-M</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXjs1ylurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997;31:183–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_14">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Magni</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Motta</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Expression of neuropeptide Y receptors in human prostate cancer cells</ArticleTitle>
                <JournalTitle>Ann Oncol</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>Suppl 2</IssueID>
                <FirstPage>S27</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11762347</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/annonc/12.suppl_2.S27</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Magni P, Motta M. Expression of neuropeptide Y receptors in human prostate cancer cells. Ann Oncol 2001;12(Suppl 2):S27–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_14">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DT</Initials>
                  <FamilyName>Burzon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Sant’Agnese</FamilyName>
                  <Particle>di</Particle>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Calcitonin receptor mRNA expression in the human prostate</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>47</VolumeID>
                <FirstPage>376</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>8633405</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(99)80456-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK283hslyltw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wu G, Burzon DT, di Sant’Agnese PA, et al. Calcitonin receptor mRNA expression in the human prostate. Urology 1996;47:376–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_14">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Leenders</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TW</Initials>
                  <FamilyName>Aalders</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Hulsbergen-van</FamilyName>
                  <Particle>de Kaa</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Ruiter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Schalken</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Expression of basal cell keratins in human prostate cancer metastases and cell lines</ArticleTitle>
                <JournalTitle>J Pathol</JournalTitle>
                <VolumeID>195</VolumeID>
                <FirstPage>563</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>11745692</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/path.993</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001;195:563–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_14">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LF</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Louie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Desai</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>2197</FirstPage>
                <LastPage>205</LastPage>
                <Occurrence Type="PID">
                  <Handle>14767470</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1207344</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXitFCmtr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lee LF, Louie MC, Desai SJ, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004;23:2197–205.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_14">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Yao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>166</VolumeID>
                <FirstPage>1807</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>15920165</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0002-9440(10)62490-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXlsFyns70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huang J, Yao JL, Zhang L, et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 2005;166:1807–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_14">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Vashchenko</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Abrahamsson</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>47</VolumeID>
                <FirstPage>147</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>15661408</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2004.09.007</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhslyht7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_14">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AI</Initials>
                  <FamilyName>Evangelou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SF</Initials>
                  <FamilyName>Winter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Huss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Bok</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Greenberg</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>91</VolumeID>
                <FirstPage>671</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>14991759</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/jcb.10771</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXitlGis7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 2004;91:671–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_14">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Adam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>143</VolumeID>
                <FirstPage>4599</FirstPage>
                <LastPage>608</LastPage>
                <Occurrence Type="PID">
                  <Handle>12446587</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/en.2002-220561</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xpt1eltrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Adam RM, Kim J, Lin J, et al. Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 2002;143:4599–608.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_14">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PD</Initials>
                  <FamilyName>Deeble</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Cox</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HF</Initials>
                  <FamilyName>Frierson</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>3663</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>17440078</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-2616</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXkt1KisLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Deeble PD, Cox ME, Frierson HF, Jr., et al. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 2007;67:3663–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_14">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Huss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>91</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>15162375</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20032</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate 2004;60:91–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_14">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Kaplan-Lefko</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Ittmann</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>55</VolumeID>
                <FirstPage>219</FirstPage>
                <LastPage>37</LastPage>
                <Occurrence Type="PID">
                  <Handle>12692788</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.10215</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219–37.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_14">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CP</Initials>
                  <FamilyName>Liao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Zhong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Saribekyan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>7525</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>17671224</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-0668</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXosVemtbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Liao CP, Zhong C, Saribekyan G, et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 2007;67:7525–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_14">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Jin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Masumori</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>5489</FirstPage>
                <LastPage>95</LastPage>
                <Occurrence Type="PID">
                  <Handle>15289359</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-03-3117</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXmtF2lsrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jin RJ, Wang Y, Masumori N, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004;64:5489–95.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_14">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Uchida</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Masumori</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Takahashi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>66</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>536</FirstPage>
                <LastPage>45</LastPage>
                <Occurrence Type="PID">
                  <Handle>16372327</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20369</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XjslWgtb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Uchida K, Masumori N, Takahashi A, et al. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate 2006;66(5):536–45.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_14">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Noda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Nishiwaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kawahara</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>346</VolumeID>
                <FirstPage>85</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>11784874</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa003034</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xkt1OlsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_14">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Yagoda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Watson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Natale</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1979</Year>
                <ArticleTitle Language="En">A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>44</VolumeID>
                <FirstPage>1553</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>498029</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(197911)44:5&lt;1553::AID-CNCR2820440502&gt;3.0.CO;2-W</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL3c%2FksVGluw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yagoda A, Watson RC, Natale RB, et al. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 1979;44:1553–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_14">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Qazi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Khandekar</FamilyName>
                </BibAuthorName>
                <Year>1983</Year>
                <ArticleTitle Language="En">Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study</ArticleTitle>
                <JournalTitle>Am J Clin Oncol</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>203</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>6681933</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00000421-198304000-00011</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL3s7kvFOnsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Qazi R, Khandekar J. Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1983;6:203–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_14">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Yagoda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>71</VolumeID>
                <FirstPage>1098</FirstPage>
                <LastPage>109</LastPage>
                <Occurrence Type="PID">
                  <Handle>7679039</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(19930201)71:3+&lt;1098::AID-CNCR2820711432&gt;3.0.CO;2-G</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s7ltlOgsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098–109.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_14">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Trump</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Marsh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LK</Initials>
                  <FamilyName>Kvols</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1990</Year>
                <ArticleTitle Language="En">A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>8</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>S91</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>2199402</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Trump DL, Marsh JC, Kvols LK, et al. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Invest New Drugs 1990; 8(Suppl 1):S91–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_14">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Canobbio</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Guarneri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Miglietta</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Carboplatin in advanced hormone refractory prostatic cancer patients</ArticleTitle>
                <JournalTitle>Eur J Cancer</JournalTitle>
                <VolumeID>29A</VolumeID>
                <FirstPage>2094</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>7507687</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0959-8049(93)90040-M</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c7ivVCgtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Canobbio L, Guarneri D, Miglietta L, et al. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 1993;29A:2094–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_14">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Miglietta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Cannobbio</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Boccardo</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>15</VolumeID>
                <FirstPage>2825</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>8669872</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xitl2itro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Miglietta L, Cannobbio L, Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 1995;15:2825–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_14">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WF</Initials>
                  <FamilyName>Jungi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Bernhard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Hurny</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK)</ArticleTitle>
                <JournalTitle>Support Care Cancer</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>462</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>9773464</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s005200050195</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1cvks1Knsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jungi WF, Bernhard J, Hurny C, et al. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer 1998;6:462–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_14">
              <CitationNumber>53</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Castagneto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Ferraris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Perachino</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <BookTitle>Weekly administration of standardized low-dose carboplatin (CBDCA) in the treatment of advanced hormone refractory prostate cancer (CRPC): a phase II study</BookTitle>
                <BibComments>Proceedings GH Cancer Symposium; abstract 243</BibComments>
              </BibBook>
              <BibUnstructured>Castagneto B, Ferraris V, Perachino M, et al. Weekly administration of standardized low-dose carboplatin (CBDCA) in the treatment of advanced hormone refractory prostate cancer (CRPC): a phase II study. Proceedings GH Cancer Symposium 2006; abstract 243.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_14">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Citrin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TF</Initials>
                  <FamilyName>Hogan</FamilyName>
                </BibAuthorName>
                <Year>1982</Year>
                <ArticleTitle Language="En">A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>50</VolumeID>
                <FirstPage>201</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>7200827</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(19820715)50:2&lt;201::AID-CNCR2820500205&gt;3.0.CO;2-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL383gvVWlsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Citrin DL, Hogan TF. A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer. Cancer 1982;50:201–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_14">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Droz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Fargeot</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Laplaige</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1987</Year>
                <ArticleTitle Language="En">Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate</ArticleTitle>
                <JournalTitle>Prog Clin Biol Res</JournalTitle>
                <VolumeID>243B</VolumeID>
                <FirstPage>235</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>3659022</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1c%2Fhs1emtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Droz JP, Fargeot P, Laplaige P, et al. Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate. Prog Clin Biol Res 1987;243B:235–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_14">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Mertens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AT</Initials>
                  <FamilyName>Porter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Reid</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report</ArticleTitle>
                <JournalTitle>J Nucl Med</JournalTitle>
                <VolumeID>33</VolumeID>
                <FirstPage>1437</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>1634933</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK38zktFWlsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mertens WC, Porter AT, Reid RH, et al. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med 1992;33:1437–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_14">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Naito</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Ueda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kotoh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>35</VolumeID>
                <FirstPage>225</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7805181</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/BF00686552</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M7gtlKrsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Naito S, Ueda T, Kotoh S, et al. Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin. Cancer Chemother Pharmacol 1995;35:225–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_14">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CK</Initials>
                  <FamilyName>Osborne</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Blumenstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ED</Initials>
                  <FamilyName>Crawford</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study</ArticleTitle>
                <JournalTitle>Eur J Cancer</JournalTitle>
                <VolumeID>28</VolumeID>
                <FirstPage>477</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>1591066</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0959-8049(05)80080-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK383ntleitA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Osborne CK, Blumenstein BA, Crawford ED, et al. Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur J Cancer 1992;28:477–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_14">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Steineck</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Reuter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements</ArticleTitle>
                <JournalTitle>Acta Oncol</JournalTitle>
                <VolumeID>41</VolumeID>
                <FirstPage>668</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>14651212</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1080/028418602321028292</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Steineck G, Reuter V, Kelly WK, et al. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol 2002;41:668–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_14">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TW</Initials>
                  <FamilyName>Flaig</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Barqawi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>107</VolumeID>
                <FirstPage>266</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>16779800</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.21982</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xnsl2mtL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Flaig TW, Barqawi A, Miller G, et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone- refractory prostate cancer. Cancer 2006;107:266–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_14">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Tu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Millikan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Mengistu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>357</VolumeID>
                <IssueID>9253</IssueID>
                <FirstPage>336</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>11210994</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(00)03639-4</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M7is1yjtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357(9253):336–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_14">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Friedland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Fleagle</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Clin Genitourin Cancer</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>131</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17026801</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3816/CGC.2006.n.029</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFOnu7fK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berry W, Friedland D, Fleagle J, et al. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006;5:131–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_14">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Curley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Slovin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>44</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>11134194</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXot1WgsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001;19:44–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_14">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Urakami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Igawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Kikuno</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>168</VolumeID>
                <FirstPage>2444</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="PID">
                  <Handle>12441936</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)64164-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XovVehsb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Urakami S, Igawa M, Kikuno N, et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002;168: 2444–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_14">
              <CitationNumber>65</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>Solit</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Morris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Slovin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>98</VolumeID>
                <FirstPage>1842</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>14584065</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.11754</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXpt1artr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Solit DB, Morris M, Slovin S, et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer 2003;98:1842–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_14">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Kikuno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Urakami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Nakamura</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>51</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1252</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2006.12.030</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kikuno N, Urakami S, Nakamura S, et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 2008;51(5):1252–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_14">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>98</VolumeID>
                <FirstPage>2592</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>14669278</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.11829</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXit1yhtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003;98:2592–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_14">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hagmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Manola</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>284</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15671557</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtVegtr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Oh WK, Hagmann E, Manola J, et al. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005;11:284–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_14">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MP</Initials>
                  <FamilyName>Hay</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">ZD-0473 AstraZeneca</ArticleTitle>
                <JournalTitle>Curr Opin Investig Drugs</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>263</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11249584</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXnvVCisbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hay MP. ZD-0473 AstraZeneca. Curr Opin Investig Drugs 2000;1:263–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_14">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>McKeage</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Lobaplatin: a new antitumour platinum drug</ArticleTitle>
                <JournalTitle>Expert Opin Investig Drugs</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>119</FirstPage>
                <LastPage>28</LastPage>
                <Occurrence Type="PID">
                  <Handle>11116285</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1517/13543784.10.1.119</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXpvFel</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs 2001;10:119–28.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_14">
              <CitationNumber>71</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Jacobus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Ryan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>112</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>521</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>18085595</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.23195</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXislCnurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008;112(3):521–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_14">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nakabayashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Sartor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Jacobus</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Response to docetaxel (D)/carboplatin (C)-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer (CRPC)</ArticleTitle>
                <JournalTitle>J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>18S</FirstPage>
                <BibComments>June 20 Supplement</BibComments>
              </BibArticle>
              <BibUnstructured>Nakabayashi M, Sartor O, Jacobus S, et al. Response to docetaxel (D)/carboplatin (C)-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer (CRPC). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_14">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CN</Initials>
                  <FamilyName>Sternberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Sartor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2009</Year>
                <ArticleTitle Language="En">Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>27</VolumeID>
                <FirstPage>5431</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>19805692</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2008.20.1228</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXhsFKkt7vJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27:5431–8.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
